Dr Reddys unveils Methylprednisolone Sodium Succinate for Injection in US
Methylprednisolone sodium succinate for Injection, USP is an anti-inflammatory glucocorticoid, which contains methylprednisolone sodium succinate as the active ingredient.
Hyderabad: Pharma major, Dr. Reddy's Laboratories Ltd., has announced the launch of Methylprednisolone Sodium Succinate for Injection, USP indicated for various conditions including arthritis, blood disorders and severe allergic reactions, in the U.S. market.
The product is a generic equivalent of SOLU-MEDROL (methylprednisolone sodium succinate for injection, USP) and has been approved by the U.S. Food and Drug Administration (USFDA).
Dr. Reddy's Methylprednisolone Sodium Succinate for Injection, USP, is supplied in 40 mg/vial,125 mg/vial single-dose vials each carton containing 25 vials; 500 mg and 1 gm multi-dose vial each carton containing 1 vial.
Methylprednisolone sodium succinate for Injection, USP is an anti-inflammatory glucocorticoid, which contains methylprednisolone sodium succinate as the active ingredient. Methylprednisolone sodium succinate, USP, is the sodium succinate ester of methylprednisolone, and it occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol; it is insoluble in chloroform and is very slightly soluble in acetone.
Read also: Dr Reddys, Binnopharm ink pact for 2 anti-bacterial brands for Russian region
Methylprednisolone sodium succinate is soluble in water; it may be administered in a small volume of diluent and is well suited for intravenous use in situations where high blood levels of methylprednisolone are required rapidly.
The SOLU-MEDROL brand and generic had U.S. sales of approximately $144 million MAT for the most recent twelve months ending in February 2022 according to IQVIA Health.
SOLU-MEDROL is a trademark of Pharmacia & Upjohn Company LLC
Read also: Dr Reddys, MediCane Health introduce medical cannabis products in Germany
